Acurx Poster Shows Ibezapolstat Beats Vancomycin in C. diff-VRE Co-Cultures
Staten Island, N.Y. – September 17, 2026 -- Acurx Pharmaceuticals (NASDAQ: ACXP) presented new in vitro data showing its lead antibiotic ibezapolstat achieved a 5.51-log reduction against Clostridioides difficile in co-culture with vancomycin-resistant Enterococcus (VRE), significantly outperforming vancomycin (p=0.0112), the current standard of care.
The poster, presented by Dr. Eugenie Bassères of the University of Houston College of Pharmacy, was unveiled at the 9th International C. difficile Symposium in Bled, Slovenia, held September 8-10, 2026.
VRE strains showed high-level resistance to vancomycin but not to ibezapolstat
All tested VRE strains exhibited vancomycin resistance with minimum inhibitory concentrations (MIC) above 128 μg/mL. Ibezapolstat and fidaxomicin maintained equivalent, lower susceptibility thresholds of 2-16 μg/mL.